17 September 2020 
EMA/CHMP/487691/2020  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Orfadin 
nitisinone 
On 17 September 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Orfadin. The marketing authorisation holder for this medicinal product is Swedish Orphan Biovitrum 
International AB. 
The CHMP adopted a new indication for the treatment of adult patients with alkaptonuria. 
For information, the full indications for Orfadin will be as follows:2 
Hereditary tyrosinemia type 1 (HT-1) 
Orfadin is indicated for the treatment of adult and paediatric (in any age range) patients with 
confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary 
restriction of tyrosine and phenylalanine. 
Alkaptonuria (AKU) 
Orfadin is indicated for the treatment of adult patients with alkaptonuria (AKU). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
 
